Pharmacokinetics, Metabolism, and Excretion of [<sup>14</sup>C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans
作者:Bill J. Smith、Yazdi Pithavala、Hai-Zhi Bu、Ping Kang、Brian Hee、Alan J. Deese、William F. Pool、Karen J. Klamerus、Ellen Y. Wu、Deepak K. Dalvie
DOI:10.1124/dmd.113.056531
日期:2014.5
(mono-oxidation/sulfone), M12a (epoxide), and an unidentified metabolite, comprising 12%, 5.7%, 5.1%, and 5.0% of the dose, respectively. The proposed mechanism to form M5 involved a carbon-carbon bond cleavage via M12a, followed by rearrangement to a ketone intermediate and subsequent Baeyer-Villiger rearrangement, possibly through a peroxide intermediate. In summary, the study characterized axitinib
在禁食的健康人类受试者(N = 8)中研究了单次口服剂量的5 mg(100μCi)[(14)C]阿西替尼的处置。阿昔替尼被快速吸收,血浆中值Tmax为2.2小时,几何平均Cmax和半衰期分别为29.2 ng / ml和10.6小时。血浆总放射性时间曲线与阿西替尼相似,但AUC较大,表明存在代谢物。在人体血浆中(0-12小时)的主要代谢物被确定为阿昔替尼N-葡萄糖醛酸(M7)和阿昔替尼亚砜(M12),在药理上是无活性的,阿西替尼分别占放射活性的50.4%,16.2%和22.5%,分别。在排泄物中,大多数受试者在用药48小时后恢复了大部分放射性。尿液,粪便中位数放射性排泄,总回收率分别为22.7%,37.0%,和59.7%。粪便的恢复在各个受试者之间是可变的(范围为2.5%-60.2%)。尿液中鉴定出的代谢物为M5(羧酸),M12(亚砜),M7(N-葡糖醛酸),M9(亚砜/ N-氧化物)和M8a(甲基羟基葡糖醛酸),分别占5